MOLECULAR PROFILING IN LOW-GRADE EC 63 3 REFERENCES 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. 2. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39. 3. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73. 4. Jamieson A, Thompson EF, Huvila J, Gilks CB, McAlpine JN. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. Int J Gynecol Cancer. 2021;31(6):907-13. 5. Leon-Castillo A, Horeweg N, Peters EEM, Rutten T, Ter Haar N, Smit V, et al. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. Gynecol Oncol. 2022;164(3):577-86. 6. Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. The Lancet. 2016;387(10023):1094-108. 7. Bosse T, Powell M, Crosbie E, Leary A, Kroep J, Han K, et al. 595 Implementation of collaborative translational research (TransPORTEC) findings in an international endometrial cancer clinical trials program (RAINBO). International Journal of Gynecologic Cancer. 2021;31(Suppl 3):A108-A9. 8. Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, et al. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol. 2018;42(5):561-8. 9. Reijnen C, Küsters-Vandevelde HVN, Prinsen CF, Massuger L, Snijders M, Kommoss S, et al. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecol Oncol. 2019;154(1):124-30. 10. Reijnen C, Küsters-Vandevelde HVN, Ligtenberg MJL, Bulten J, Oosterwegel M, Snijders M, et al. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome. Int J Cancer. 2020;147(2):478-89. 11. van Weelden WJ, van der Putten LJM, Inda MA, van Brussel A, Snijders M, Schriever LMM, et al. Oestrogen receptor pathway activity is associated with outcome in endometrial cancer. Br J Cancer. 2020;123(5):785-92. 12. van der Putten LJ, Visser NC, van de Vijver K, Santacana M, Bronsert P, Bulten J, et al. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study. Br J Cancer. 2016;115(6):716-24. 13. Reijnen CV, S.W.; Draak, R.; Sweegers, S.; Snijders, M.P.L.M.; Gestel van, P.; Eikelenboom, A.; Pijnenborg, J.M.A.;, Bulten, J.; Küsters-Vandevelde, H.V.N. Pure and mixed clear cell carcinoma of the endometrium: a molecular and immunohistochemical analysis study. 2022. 14. Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180-8. 15. León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, et al. Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol. 2020;250(3):312-22. 16. Eijkelenboom A, Kamping EJ, Kastner-van Raaij AW, Hendriks-Cornelissen SJ, Neveling K, Kuiper RP, et al. Reliable Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue Using Single Molecule Tags. J Mol Diagn. 2016;18(6):851-63. 17. WHO classification of Tumours 5th ed2020 2020. 18. McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol. 2018;244(5):538-49. 19. Köbel M, Nelson GS. Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538549. J Pathol. 2018;245(2):249-50.
RkJQdWJsaXNoZXIy MTk4NDMw